Gemcitabine controlled release - TARIS Biomedical
Alternative Names: Gemcitabine-releasing intravesical system - TARIS; GemRIS™; JNJ-17000139; JNJ-17000139-AAC; RIS/gemcitabine; TAR-200Latest Information Update: 09 May 2024
At a glance
- Originator AstraZeneca; TARIS Biomedical
- Developer Bristol-Myers Squibb; Janssen Research & Development; TARIS Biomedical
- Class Amines; Antineoplastics; Deoxyribonucleosides; Fluorinated hydrocarbons; Ketones; Pyrimidine nucleosides; Pyrimidines; Small molecules
- Mechanism of Action Antimetabolites; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Bladder cancer
Most Recent Events
- 03 May 2024 Updated efficacy and adverse effect data from the phase II SunRISe-1 trial in Bladder cancer released by Johnson & Johnson
- 09 Apr 2024 Phase-III clinical trials in Bladder cancer (Recurrent) in United Kingdom, South Korea, USA (Intravesicular) (NCT06211764)
- 23 Jan 2024 Janssen Research & Development plans a phase III SunRISe-5 trial for Bladder cancer (Recurrent) in April 2024 (Intravesicular) (NCT06211764)